Beijing GD Initiative Cell Therapy

Beijing GD Initiative Cell Therapy is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for cancer. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) therapies targeting various hematological malignancies and solid tumors. Its lead candidate, GDI-01, is a CD19-targeted CAR-T therapy currently in clinical trials for B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. Beijing GD Initiative Cell Therapy aims to leverage its proprietary cell engineering platforms to provide more effective and accessible treatments for patients with refractory or relapsed cancers. The company maintains its own GMP-compliant manufacturing facilities to support clinical development and future commercialization.